CN102015674B - 多巴胺神经传递调节剂 - Google Patents

多巴胺神经传递调节剂 Download PDF

Info

Publication number
CN102015674B
CN102015674B CN200980115129.4A CN200980115129A CN102015674B CN 102015674 B CN102015674 B CN 102015674B CN 200980115129 A CN200980115129 A CN 200980115129A CN 102015674 B CN102015674 B CN 102015674B
Authority
CN
China
Prior art keywords
methyl
methylsulfonyl
benzodioxin
amine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980115129.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102015674A (zh
Inventor
C·索内松
P·斯文松
M·安德松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CN102015674A publication Critical patent/CN102015674A/zh
Application granted granted Critical
Publication of CN102015674B publication Critical patent/CN102015674B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
CN200980115129.4A 2008-04-29 2009-04-28 多巴胺神经传递调节剂 Expired - Fee Related CN102015674B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200800600 2008-04-29
DKPA200800600 2008-04-29
US4905708P 2008-04-30 2008-04-30
US61/049,057 2008-04-30
PCT/EP2009/055140 WO2009133110A1 (en) 2008-04-29 2009-04-28 Modulators of dopamine neurotransmission

Publications (2)

Publication Number Publication Date
CN102015674A CN102015674A (zh) 2011-04-13
CN102015674B true CN102015674B (zh) 2014-10-29

Family

ID=40937591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980115129.4A Expired - Fee Related CN102015674B (zh) 2008-04-29 2009-04-28 多巴胺神经传递调节剂

Country Status (10)

Country Link
US (1) US8492372B2 (enExample)
EP (1) EP2271638B1 (enExample)
JP (1) JP5548853B2 (enExample)
CN (1) CN102015674B (enExample)
AT (1) ATE522515T1 (enExample)
AU (1) AU2009242095A1 (enExample)
CA (1) CA2722986A1 (enExample)
DK (1) DK2271638T3 (enExample)
MX (1) MX2010011498A (enExample)
WO (1) WO2009133110A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2271634T3 (da) 2008-04-29 2014-05-05 Integrative Res Lab Sweden Ab Modulatorer af dopamin-neurotransmission
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
JP5876140B2 (ja) 2011-04-19 2016-03-02 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のドーパミン作動性及びｎｍｄａ受容体介在のグルタミン酸作動性神経伝達の新規なモジュレータ
CN105979942B (zh) * 2013-12-12 2018-12-07 比皮艾思药物研发有限公司 用于治疗或缓解疼痛的氨基磺酸酯衍生物
CN106928147A (zh) * 2017-03-14 2017-07-07 华东师范大学 三环二萜类似物及其制备方法、及其在制备抗前列腺癌药物中的应用
WO2020239568A1 (en) 2019-05-24 2020-12-03 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058980A (en) * 1962-10-16 Substitution products of benzo-
US2906757A (en) * 1959-09-29 Their preparation
DE1110175B (de) * 1957-01-08 1961-07-06 Rhone Poulenc Sa Verfahren zur Herstellung von Benzodioxanderivaten
US3851062A (en) * 1973-08-01 1974-11-26 Minnesota Mining & Mfg Method of suppressing weight gain
US4056540A (en) * 1974-01-01 1977-11-01 Bristol-Myers Company 4-Phenyl-1,3-benzodioxans
US5126366A (en) * 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
US5189171A (en) * 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5166367A (en) * 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
WO1996038435A1 (en) 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
AR004229A1 (es) * 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
JP2005505586A (ja) 2001-10-04 2005-02-24 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
NZ550441A (en) 2004-05-05 2009-07-31 Hoffmann La Roche Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
KR101245075B1 (ko) * 2004-06-08 2013-03-18 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
BRPI0610046A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AR060493A1 (es) * 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
DK2271634T3 (da) * 2008-04-29 2014-05-05 Integrative Res Lab Sweden Ab Modulatorer af dopamin-neurotransmission
EP2271635A1 (en) 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission

Also Published As

Publication number Publication date
MX2010011498A (es) 2010-11-12
CA2722986A1 (en) 2009-11-05
US20110112065A1 (en) 2011-05-12
AU2009242095A1 (en) 2009-11-05
EP2271638A1 (en) 2011-01-12
JP2011518859A (ja) 2011-06-30
DK2271638T3 (da) 2011-11-28
WO2009133110A1 (en) 2009-11-05
ATE522515T1 (de) 2011-09-15
EP2271638B1 (en) 2011-08-31
US8492372B2 (en) 2013-07-23
JP5548853B2 (ja) 2014-07-16
CN102015674A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
CN102036976B (zh) 多巴胺神经传递的调节剂
CN102015674B (zh) 多巴胺神经传递调节剂
CN101076517B (zh) 作为多巴胺神经传递调节剂的取代的哌啶类
US9120728B2 (en) Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
RU2418787C2 (ru) 3,5-дизамещенные фенилпиперидины в качестве модуляторов нейротрансмиссии допамина
US9035073B2 (en) 3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP2367786B1 (en) Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP2367785B1 (en) Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
KR102595892B1 (ko) 피질 카테콜아민성 신경전달의 조절자로서 유용한 신규한 아제티딘 유도체
HK1192877B (en) Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB

Free format text: FORMER OWNER: NSAB AF NEUROSEARCH SWEDEN AB

Effective date: 20141225

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20141225

Address after: Gothenburg

Patentee after: NEUROSEARCH A/S

Address before: Denmark and Rupp

Patentee before: NSAB Filial af NeuroSearch Sweden AB Sverige

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

CF01 Termination of patent right due to non-payment of annual fee